About Us
Jiuzhitang Maker
Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (hereinafter referred to as Jiuzhitang Maker) was established in March 2018 with a registered capital of 200 million yuan. The company is a biotechnology firm dedicated to the production, research and development, and sales of stem cell-based pharmaceuticals and regenerative medicine products. Jiuzhitang Maker has already completed the construction of a large-scale stem cell drug R&D and manufacturing facility at the China Pharmaceutical Valley—Beijing Daxing Biomedical Base—that meets GMP standards set by China, the United States, and the European Union. The facility boasts an office and production area of approximately 4,800 square meters, featuring four independent B+A-grade clean zones capable of producing clinical-grade stem cell drugs compliant with both Chinese and U.S. regulatory requirements for pharmaceutical submissions.
Jiuzhitang Maker has introduced stem cell technology from the U.S.-based company Stemedica Cell Technologies, further refining and enhancing it to develop a unique stem cell production and quality system.
Jiuzhitang Maker has been designated as one of the "Ten Key Enterprises" by the Daxing District Development and Reform Commission and the Biomedical Base Committee. The company has also successively earned prestigious recognitions, including "Zhongguancun High-Tech Enterprise," "National High-Tech Enterprise," "Zhongguancun Golden Seed Enterprise," "First Batch of Science and Technology-Based SMEs Approved by the Ministry of Science and Technology," "Postdoctoral Research Workstation," "District-Level Enterprise R&D Institution," and "Beijing Specialized, Fine, and Innovative Enterprise." Additionally, Jiuzhitang Maker was honored with accolades such as "Top 50 Innovative Chinese Biopharmaceutical Companies in 2020," "Outstanding Corporate Social Responsibility Enterprise of 2020," the "2021 China Biopharmaceutical Company Growth Award," and two major awards at the 5th Brand Power China Economic Forum in 2021. Furthermore, the company played a key role in drafting the "Guidelines for Ethical Evaluation of Stem Cell Sources."
In February 2020, Jiuzhitang Maker’s clinical trial for a new stem-cell-based drug received approval (Acceptance No.: JXSL1900126), targeting ischemic stroke as its indication. This marks the first clinical trial approved by the CDE that utilizes imported stem cells, the first to explore stem cells for treating major neurological conditions, and the first to employ bone marrow-derived mesenchymal stem cells. The trial holds landmark significance for the development of China’s stem-cell industry. On January 12, 2021, the ASSIST clinical trial officially kicked off and is currently being conducted at several hospitals, including Beijing Tiantan Hospital, Affiliated to Capital Medical University.
In June 2023, Jiuzhitang Maker received approval (Acceptance No.: CXSL2300202) for the clinical trial of its second stem-cell-based new drug, targeting autoimmune alveolar proteinosis (aPAP). On November 1, 2023, the clinical trial officially kicked off, with Jiuzhitang Maker collaborating with the First Affiliated Hospital of Guangzhou Medical University to conduct a Phase IIa clinical study evaluating hBMMSC therapy for treating aPAP. This marks Jiuzhitang Maker’s first domestically developed, Class I bioproduct—a novel stem-cell drug—and also represents the world’s first clinical trial exploring human bone marrow mesenchymal stem cells as a treatment for autoimmune alveolar proteinosis (aPAP).
In March 2025, Jiuzhitang Maker received approval (Acceptance No.: CXSL2400859) for the clinical trial of its third stem-cell-based new drug, targeting autism spectrum disorder. This marks the nation’s first clinical trial using human bone marrow mesenchymal stem cells to treat autism.
Jiuzhitang Maker will uphold Jiuzhitang’s over-370-year-old family motto—“A pharmacist should devote full effort, and a physician should act with integrity”—and leverage its advanced production technologies and robust industrialization capabilities to actively drive the launch of stem-cell therapies in the domestic market.
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy